Immutep (IMMP) Competitors

Immutep (NASDAQ:IMMP) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, community ranking, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Do institutionals & insiders hold more shares of IMMP or AUPH?

2.3% of Immutep shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 3.1% of Immutep shares are held by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media refer more to IMMP or AUPH?

In the previous week, Aurinia Pharmaceuticals had 5 more articles in the media than Immutep. MarketBeat recorded 7 mentions for Aurinia Pharmaceuticals and 2 mentions for Immutep. Aurinia Pharmaceuticals' average media sentiment score of 1.63 beat Immutep's score of 0.94 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immutep	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has stronger earnings & valuation, IMMP or AUPH?

Immutep has higher earnings, but lower revenue than Aurinia Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immutep	$5.14M	52.56	-$28.01M	N/A	N/A
Aurinia Pharmaceuticals	$247.30M	4.42	-$78.02M	$0.28	28.89

Is IMMP or AUPH more profitable?

Immutep has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Immutep's return on equity of 0.00% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immutep	N/A	N/A	N/A
Aurinia Pharmaceuticals	-10.23%	-4.41%	-3.07%

Do analysts prefer IMMP or AUPH?

Immutep currently has a consensus price target of $7.00, suggesting a potential upside of 278.38%. Aurinia Pharmaceuticals has a consensus price target of $11.50, suggesting a potential upside of 42.15%. Given Immutep's higher possible upside, equities analysts plainly believe Immutep is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immutep	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, IMMP or AUPH?

Immutep has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.

Does the MarketBeat Community prefer IMMP or AUPH?

Aurinia Pharmaceuticals received 265 more outperform votes than Immutep when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 72.22% of users gave Immutep an outperform vote.

Company	Underperform	Outperform
Immutep	Outperform Votes 312 72.22%	Underperform Votes 120 27.78%
Aurinia Pharmaceuticals	Outperform Votes 577 73.41%	Underperform Votes 209 26.59%

Summary

Aurinia Pharmaceuticals beats Immutep on 8 of the 15 factors compared between the two stocks.